Supporting information

1,1'-Dibenzyl-bis-(triazolyl)diphosphine dioxide: a new efficient organocatalyst for silicon tetrachloride-mediated enantioselective Abramov-type phosphonylation of aldehydes with trialkyl phosphites

Nicolas Sevrain,^a Jean-Noel Volle,^a Jean-Luc Pirat,^a Tahar Ayad^{*a,b} and David Virieux^{*a}

^aInstitut Charles Gerhardt, CNRS UMR 5253, Ecole Nationale Supérieure de Chimie de Montpellier, 8 Rue de l'Ecole Normale, 34 296 Montpellier, France. ^bPSL Research University, Chimie Paristech-CNRS, Institut de Recherche de Chimie Paris, 75 005 Paris, France

tahar.ayad@chimie-paristech.fr, david.virieux@enscm.fr

Table of contents.

I.	General informations	. 1
II.	Typical procedure for phosphonylation of aldehydes	.1
III.	Description of phosphonylation products 2a-p	. 2
IV.	1H and 13C NMR Spectra of phosphonylation products 4a-p	.7
V.	HPLC chromatogram of phosphonylation products 4a-p	23

I. General informations

All reactions were run under an atmosphere of nitrogen using standard Schlenk techniques otherwise stated. Liquid aldehydes were distilled under reduced pressure before use. Reaction vessels were flame-dried under vacuum and cooled under a stream of nitrogen. Solvents were carefully dried by conventional methods or were purified with an MBRAUN Solvent Purification System and degassed prior to use. Reactions were monitored by thin layer chromatography (TLC) on silica gel pre-coated plastic sheets (0.2 mm, Machery-Nagel). Visualization of the developed chromatogram was performed by UV light and revealed using either potassium permanganate or phosphomolybdic acid solutions. Flash column chromatography (FC) was performed on Merck silica gel (60, particle size 0.040-0.063 mm). ¹H, ¹³C, ¹⁹F and ³¹P NMR spectra were recorded with a bruker Avance 400 MHz spectrometer. Chemical shifts are reported in delta (δ) units, part per million (ppm) downfield from tetramethylsilane (TMS) relative to the residual deuterated solvent peaks. Coupling constants are reported in Hertz (Hz). The following abbreviations are used: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad signal. Enantiomeric ratios were determined by HPLC analysis measured on a Shimadzu®LC 20 AHPLC with a UV/visible detector at 195nm using a chiral stationary phase column specified in the individual experiment, by comparing the samples with the appropriate racemic mixtures. Optical rotations were measured on a polarimeter at 589 nm (sodium lamp) with a Bellingham + Stanley®ADP 440 Polarimeter. High resolution mass spectroscopic (HRMS) analysis were measured on a Xevo G2 Q TOF spectrometer using the electrospray method by the Laboratoire de Mesures Physiques of the University of Montpellier

II. Typical procedure for phosphonylation of aldehydes

Aldehyde (0.5 mmol), iPr_2NEt (1.5 mmol), nBu_4NI (0.5 mmol) and (S)-1,1'-dibenzyl-bis-(triazolyl)diphosphine dioxide (5 mol %, 0.025 mmol) were mixed in anhydrous Et_2O (2.0 mL) at -78 °C

in a flame dried Schlenk tube under nitrogen atmosphere. To this solution was added the desired phosphite (0.60 mmol) and then silicon tetrachloride (1M dichloromethane solution, 0.75 mL, 0.75 mmol) was introduced over 10min using a syringe. The reaction progress was monitored by TLC (ethyl acetate). Upon completion, deionized water (2 mL), saturated aqueous NaHCO₃ (5 mL), and ethyl acetate (5 mL) were carefully added to the reaction mixture. After being stirred for approximatively 1 h, the reaction mixture was filtered through a short Celite pad. The two phases were then separated and the aqueous phase was extracted with ethyl acetate (3×5 mL). The combined organic layers were washed with brine, dried over anhydrous MgSO₄, filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography (silica gel, hexane /ethyl acetate : 50/50 to 0/100) to give the corresponding α -hydroxyphosphonates. The enantiomeric ratios were determined by HPLC using IC or AS-H Chiralpak columns.

III. Description of phosphonylation products 2a-p



Dimethyl (*R***)-(hydroxy(phenyl)methyl)phosphonate (4b) (known product)**¹: Yield = 87%; $[\alpha]^{24}_{D}$ = +30.4 (c 1.05, CHCl₃) [Lit.¹ $[\alpha]^{27}_{D}$ = +21.5 (c 0.80, CHCl₃) for 28% ee (*R*)]. HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 41.77 min (*S*, minor), t_{R} = 45.19 min (*R*, major); e.r. = 84.6:15.4. ¹H NMR (400.13 MHz,

CDCl₃) δ 7.50–7.48 (m, 2H), 7.40–7.31 (m, 3H), 5.06 (d, *J* = 10.9 Hz, 1H), 3.71 (d, *J* = 10.5 Hz, 3H), 3.67 (d, *J* = 10.4 Hz, 3H). ¹³C NMR (100.61 MHz, CDCl₃) δ 136.48 (d, *J* = 2.1 Hz), 128.54 (d, *J* = 2.5 Hz, two carbons), 128.39 (d, *J* = 3.2 Hz), 127.17 (d, *J* = 5.9 Hz, two carbons), 70.78 (d, *J* = 159.4 Hz), 54.07 (d, *J* = 7.0 Hz), 53.78 (d, *J* = 7.4 Hz). ³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 23.47 (s).



Diethyl (*R*)-(hydroxy(phenyl)methyl)phosphonate (4a) (known product)¹: Yield = 91%; $[\alpha]^{24}_{D}$ = 22.0 (c 1.09, CHCl₃) [Lit.¹ $[\alpha]^{27}_{D}$ = +14.8 (c 1.01, CHCl₃) for 41% ee (*R*)]. HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 26.96 min (*R*, major), t_{R} = 32.14 min (*S*, minor); e.r. = 84.5:15.5. ¹H NMR (400.13 MHz,

CDCl₃) δ 7.50–7.48 (m, 2H), 7.38–7.29 (m, 3H), 5.02 (dd, J = 10.8, J = 2.7 Hz, 1H), 4.10–3.92(m, 4H), 3.63–3.50 (m, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.21 (t, J = 7.1 Hz, 3H); ¹³C NMR (100.61 MHz, CDCl₃) δ 136.85 (d, J = 1.9 Hz), 128.28 (d, J = 2.5 Hz, two carbons), 128.08 (d, J = 3.2 Hz), 127.22 (d, J = 5.8 Hz, two carbons), 70.86 (d, J = 159.2 Hz), 63.44 (d, J = 7.0 Hz), 63.09 (d, J = 7.3 Hz), 16.46 (d, J = 5.6 Hz), 16.43 (d, J = 5.5 Hz); ³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 21.35 (s).



Dibutyl (*R***)-(hydroxy(phenyl)methyl)phosphonate (4c) (known product)**¹: Yield = 79%; $[\alpha]^{24}_{D}$ = +11.5 (c 1.04, CHCl₃) [Lit.¹ $[\alpha]^{27}_{D}$ = +8.8 (c 1.05, CHCl₃) for 33% ee (*R*)]. HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 16.49 min (*R*, major), t_{R} = 19.11 min (*S*, minor); e.r. = 78.5:11.5. ¹H NMR (400.13 MHz,

CDCl₃) δ 7.49–7.46 (m, 2H), 7.37–7.28 (m, 3H), 5.02 (dd, *J* = 10.8, *J* = 4.9 Hz, 1H), 4.02–3.86 (m, 4H), 3.65–3.61 (m, 1H), 1.63–1.49 (m, 4H), 1.39–1.24 (m, 4H), 0.89 (t, *J* = 7.4 Hz, 4H), 0.86 (t, *J* = 7.4 Hz, 1H). ¹³C NMR (100.61 MHz, CDCl₃) δ 137.04 (d, *J* = 1.8 Hz), 128.14 (d, *J* = 2.5 Hz, two carbons), 127.91 (d, *J* = 3.1 Hz), 127.19 (d, *J* = 5.8 Hz, two carbons), 70.78 (d, *J* = 159.7 Hz), 67.06 (d, *J* = 7.3 Hz), 66.65 (d, *J* = 7.6 Hz), 32.53 (d, *J* = 5.7 Hz), 32.52 (d, *J* = 5.6 Hz), 18.62 (d, *J* = 4.6 Hz, two carbons), 13.59 (d, *J* = 1.4 Hz, two carbons).³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 21.27 (s).



Diisopropyl (*R***)-(hydroxy(phenyl)methyl)phosphonate (4d) (known product)**¹: Yield r = 92%; $[\alpha]^{24}_{D}$ = +22.2 (c 1.08, CHCl₃) [Lit.¹ $[\alpha]^{27}_{D}$ = +12.2 (c 1.01, CHCl₃) for 40% ee (*R*)].HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm,

¹ K. Nakanishi, S. Kotani, M. Sugiura, M. Nakajima, Tetrahedron, 2008,64, 6415

 $t_{\rm R}$ = 12.33 min (*R*, major), $t_{\rm R}$ = 17.07 min (*S*, minor); e.r. = 88.4:11.6. ¹H NMR (400.13 MHz, CDCl₃) δ 7.50–7.48 (m, 2H), 7.37–7.27 (m, 3H), 4.96 (d, *J* = 10.9 Hz, 1H), 4.66–4.57 (m, 2H), 1.28 (d, *J* = 6.2, 3H), 1.27 (d, *J* = 6.2, 3H), 1.24 (d, *J* = 6.2 Hz, 3H), 1.13 (d, *J* = 6.2 Hz, 3H). ¹³C NMR (100.61 MHz, CDCl₃) δ 137.06 (d, *J* = 1.9 Hz), 128.12 (d, *J* = 2.5 Hz, two carbons), 127.89 (d, *J* = 3.1 Hz), 127.39 (d, *J* = 5.8 Hz, two carbons), 71.16 (d, *J* = 160.4 Hz), 72.03 (d, *J* = 7.3 Hz), 71.67 (d, *J* = 7.6 Hz), 24.26 (d, *J* = 3.1 Hz), 24.13 (d, *J* = 3.6 Hz), 23.96 (d, *J* = 5.0 Hz), 23.63 (d, *J* = 5.5 Hz). ³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 19.74 (s).

Diisopropyl (R)-(hydroxy(2-methoxyphenyl)methyl)phosphonate (4e): Yield = 79%; $[\alpha]^{24}_{D}$ = +18.0 (c 1.11, CHCl₃). HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 25.55 min (*R*, major), t_{R} = 48.97 min (*S*, minor); e.r. = 72:28. ¹H NMR (400.13 MHz, CDCl₃) δ 7.53 (dt, *J* = 7.6, 1.9 Hz, 1H), 7.28–7.23 (m,

1H), 6.97 (t, J = 7.5 Hz, 1H), 6.86 (d, J = 8.3 Hz, 1H), 5.34 (d, J = 12.4 Hz, 1H), 4.77–4.66 (m, 1H), 4.59–4.48 (m, 1H), 3.85 (brs, 1H), 3.83 (s, 3H), 1.30 (d, J = 6.6 Hz, 3H), 1.29 (d, J = 6.5 Hz, 3H), 1.23 (d, J = 6.2 Hz, 3H), 1.02 (t, J = 5.8 Hz, 3H).¹³C NMR (100.61 MHz, CDCl₃) δ 156.67 (d, J = 6.6 Hz), 128.87, 128.86 (d, J = 7.0 Hz), 125.80, 120.55 (d, J = 2.7 Hz), 110.29 (d, J = 2.0 Hz), 71.58 (d, J = 7.4 Hz), 71.17 (d, J = 7.4 Hz), 65.08 (d, J = 163.5 Hz), 55.35 (s), 24.23 (d, J = 2.9 Hz), 24.06 (d, J = 3.4 Hz), 23.83 (d, J = 5.2 Hz), 23.33 (d, J = 5.7 Hz). ³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 20.71 (s). HRMS (ESI, M+H⁺) m/z calcd for C₁₄H₂₄O₅P: 303.1361, found 303.1357.



Diisopropyl (*R***)-(hydroxy(3-methoxyphenyl)methyl)phosphonate (4f):** Yield = 93%; $[\alpha]^{24}_{D}$ = +10.8 (c 1.11, CHCl₃). HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 34.82 min (*S*, minor). t_{R} = 41.01 min (*R*, major); e.r. = 88.5:11.5. ¹H NMR (400.13 MHz, CDCl₃) δ 7.23 (t, *J* = 7.9 Hz, 1H),

7.08–7.04 (m, 2H), 6.82 (d, *J* = 8.2 Hz, 1H), 4.93 (d, *J* = 11.0 Hz, 1H), 4.69–4.56 (m, 2H), 4.11 (brs, 1H), 3.79 (s, 3H), 1.26 (d, *J* = 6.2 Hz, 9H), 1.15 (d, *J* = 6.2 Hz, 3H).¹³C NMR (100.61 MHz, CDCl₃) δ 159.34 (d, *J* = 2.5 Hz), 138.77 (d, *J* = 1.3 Hz), 128.83 (d, *J* = 2.4 Hz), 119.80 (d, *J* = 6.0 Hz), 113.72 (d, *J* = 3.1 Hz), 112.46 (d, *J* = 5.6 Hz), 71.92 (d, *J* = 7.4 Hz), 71.53 (d, *J* = 7.6 Hz), 70.89 (d, *J* = 161.3 Hz), 55.12, 24.10 (d, *J* = 14.6 Hz), 24.16 (d, *J* = 3.0 Hz), 24.07 (d, *J* = 15.2 Hz), 24.01 (d, *J* = 3.6 Hz), 23.86 (d, *J* = 5.0 Hz), 23.54 (d, *J* = 5.5 Hz).³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 19.79 (s). HRMS (ESI, M+H⁺) *m/z* calcd for C₁₄H₂₄O₅P: 303.1361, found 303.1360.



Diisopropyl (*R*)-(hydroxy(4-methoxyphenyl)methyl)phosphonate (4j) (known product)²: Yield = 95%; $[\alpha]^{24}_{D}$ = +15.5 (c 1.03, CHCl₃) [lit.² $[\alpha]^{22}_{D}$ =-7.5 (c 0.80, CHCl₃) for 35% ee (*S*)]. HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 19.14 min (*R*, major), t_{R} = 28.03 min (*S*, minor); e.r. =

85.5:14.5.¹H NMR (400.13 MHz, CDCl₃) δ 7.41 (dd, *J* = 8.7, 2.1 Hz, 2H), 6.89 (d, *J* = 8.6 Hz, 2H), 4.88 (dd, *J* = 9.9, 4.7 Hz, 1H), 4.68–4.56 (m, 2H), 3.81 (s, 3H), 2.79 (dd, *J* = 10.2, 4.8 Hz, 1H), 1.30–1.25 (m, 9H), 1.13 (d, *J* = 6.2 Hz, 3H).¹³C NMR (100.61 MHz, CDCl₃) δ 159.36 (d, *J* = 2.8 Hz), 129.18 (d, *J* = 1.7 Hz), 128.73 (d, *J* = 6.1 Hz), 113.55 (d, *J* = 2.1 Hz), 71.86 (d, *J* = 7.3 Hz), 71.52 (d, *J* = 7.6 Hz), 70.64 (d, *J* = 162.7 Hz), 55.28 (s), 24.25 (d, *J* = 3.0 Hz), 24.12 (d, *J* = 3.5 Hz), 23.97 (d, *J* = 5.0 Hz), 23.66 (d, *J* = 5.4 Hz).³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 20.00 (s).



Diisopropyl (*R*)-(hydroxy(4-methylphenyl)methyl)phosphonate (4h) (known product)²: Yield = 94%; $[\alpha]^{24}_{D}$ = +23.0 (c 1.04, CHCl₃). HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 14.40 min (*R*, major), t_{R} = 23.31 min (*S*, minor); e.r. = 86.5:13.5. ¹H NMR (400.13 MHz, CDCl₃) δ 7.37 (dd,

² K. V. Zaitsev, M. V. Bermeshev, A. A. Samsonov, J. F. Oprunenko, A. V. Churakov, J. A. L. Howard, S. S. Karlov, G. S. Zaitseva, *New J. Chem.*, **2008**, *32*, 1415.

J = 8.1, 2.1 Hz, 2H), 7.16 (d, J = 8.1 Hz, 2H), 4.91 (dd, J = 10.5, 4.8 Hz, 1H), 4.69–4.55 (m, 2H), 2.84 (dd, J = 10.1, 4.4 Hz, 1H), 2.34 (d, J = 1.7 Hz, 3H), 1.29–1.27 (m, 9H), 1.25 (d, J = 6.2 Hz, 3H), 1.13 (d, J = 6.2 Hz, 3H). ¹³C NMR (100.61 MHz, CDCl₃) δ 137.44 (d, J = 3.2 Hz), 134.08 (d, J = 1.8 Hz), 128.76 (d, J = 2.4 Hz), 127.32 (d, J = 6.0 Hz), 71.88 (d, J = 7.3 Hz), 71.52 (d, J = 7.6 Hz), 70.93 (d, J = 161.4 Hz), 24.24 (d, J = 3.1 Hz), 24.11 (d, J = 3.6 Hz), 23.94 (d, J = 5.0 Hz), 23.62 (d, J = 5.5 Hz), 21.23 (d, J = 0.9 Hz).³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 19.98 (s).



Diisopropyl (*R***)-(hydroxy(2-fluorophenyl)methyl)phosphonate (4i):** Yield = 81%; $[\alpha]^{24}{}_{D}$ = +14.0 (c 1.14 CHCl₃). HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 9.11 min (*R*, major), t_{R} = 12.15 min (*S*, minor); e.r. = 66.5:33.5. ¹H NMR (400.13 MHz, CDCl₃) δ 7.71–7.67 (m, 1H), 7.29–7.24 (m, 1H), 7.18–

7.14 (m, 1H), 7.04–6.99 (m, 1H), 5.32 (d, J = 11.6 Hz, 1H), 4.76–4.58 (m, 3H), 1.33 (d, J = 6.2 Hz, 3H), 1.28–1.24 (m, 6H), 1.14 (d, J = 6.2 Hz, 3H).¹³C NMR (100.61 MHz, CDCl₃) δ 159.91 (dd, J = 247.0, 6.9 Hz), 129.46 (dd, J = 8.2, 3.1 Hz), 129.26 (dd, $J_{CF} = J_{CP} = 3.7$ Hz), 125.02 (d, J = 13.7 Hz), 124.17 (dd, $J_{CF} = J_{CP} = 3.1$ Hz), 114.96 (dd, J = 22.1, 2.2 Hz), 72.35 (d, J = 7.5 Hz), 71.93 (d, J = 7.6 Hz), 64.12 (dd, J = 165.1, 3.2 Hz), 24.29 (d, J = 3.1 Hz), 24.10 (d, J = 3.6 Hz), 23.92 (d, J = 5.0 Hz), 23.55 (d, J = 5.6 Hz). ³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 19.22 (d, J = 6.6 Hz). HRMS (ESI, M+H⁺) m/z calcd for C₁₃H₂₁O₄FP: 291.1161, found 291.1152.



Diisopropyl (*R***)-(hydroxy(3-fluorophenyl)methyl)phosphonate (4j):** Yield = 93%; $[\alpha]^{24}_{D}$ = +19.3 (c 1.24, CHCl₃). HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 7.60 min (*S*, minor), t_{R} = 8.37 min (*R*, major); e.r. = 81:19.¹H NMR (400.13 MHz, CDCl₃) δ 7.32–7.23 (m, 3H), 7.00–6.95 (m, 1H), 4.96

(d, *J* = 8.6 Hz, 1H), 4.70–4.61 (m, 2H), 4.22 (brs, 1H), 1.28–1.26 (m, 9H), 1.18 (d, *J* = 6.2 Hz, 3H).¹³C NMR (100.61 MHz, CDCl₃) δ 162.79 (dd, *J* = 245.3, 2.9 Hz), 139.72 (d, *J* = 7.4 Hz), 129.55 (dd, *J* = 8.1, 2.5 Hz), 122.95 (dd, *J* = 5.7, 2.9 Hz), 114.73 (dd, *J* = 21.2, 3.1 Hz), 114.29 (dd, *J* = 22.8, 5.4 Hz), 72.37 (d, *J* = 7.4 Hz), 72.00 (d, *J* = 7.7 Hz), 70.61 (dd, *J* = 160.3, 1.8 Hz), 24.26 (d, *J* = 3.2 Hz), 24.11 (d, *J* = 3.7 Hz), 23.99 (d, *J* = 5.0 Hz), 23.71 (d, *J* = 5.4 Hz).³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 19.07 (s). HRMS (ESI, M+H⁺) *m/z* calcd for C₁₃H₂₁O₄FP: 291.1161, found 291.1152.



Diisopropyl (*R***)-(hydroxy(4-fluorophenyl)methyl)phosphonate (4k):** Yield = 95%; $[\alpha]^{24}{}_{D}$ = +25.6 (c 1.09, CHCl₃) [lit² $[\alpha]^{22}{}_{D}$ =-80.0 (c 0.80, CHCl₃) for 40% ee (*S*)]. HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 8.54 min (*R*, major), t_{R} = 9.65min (*S*, minor); e.r. = 89:11. ¹H NMR (400.13 MHz,

CDCl₃) δ 7.48–7.44 (m, 2H), 7.02 (t, *J* = 8.5 Hz, 2H), 4.93 (dd, *J* = 10.4, 5.2 Hz, 1H), 4.69–4.57 (m, 2H), 4.38 (dd, *J* = 7.7, 5.4 Hz, 1H), 1.27–1.24 (m, 9H), 1.16 (d, *J* = 6.2 Hz, 3H).¹³C NMR (100.61 MHz, CDCl₃) δ 162.47 (dd, *J* = 245.8, 3.4 Hz), 133.09 (dd, *J* = 3.0, 1.8 Hz), 129.09 (dd, *J* = 8.1, 5.9 Hz, two carbons), 114.91 (dd, *J* = 21.5, 2.4 Hz, two carbons), 72.11 (d, *J* = 7.4 Hz), 71.70 (d, *J* = 7.7 Hz), 70.35 (d, *J* = 162.5 Hz), 24.19 (d, *J* = 3.2 Hz), 24.04 (d, *J* = 3.7 Hz), 23.96 (d, *J* = 4.9 Hz), 23.65 (d, *J* = 5.4 Hz).³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 19.50 (d, *J* = 4.9 Hz). HRMS (ESI, M+H⁺) *m/z* calcd for C₁₃H₂₁O₄FP: 291.1161, found 291.1150.



Diisopropyl (*R***)-(hydroxy(4-chlorophenyl)methyl)phosphonate (4I):** Yield = 93%; $[\alpha]^{24}_{D}$ = +20.8 (c 1.15, CHCl₃). HPLC analysis: Chiralpak AS-H column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 6.66 min (*R*, major), t_{R} = 8.41min (*S*, minor); e.r. = 86:14. ¹H NMR (400.13 MHz, CDCl₃) δ 7.42 (dd, *J* = 8.6, 2.1 Hz, 2H), 7.32 (d, *J*

= 8.5 Hz, 2H), 4.94 (d, J = 10.7 Hz, 1H), 4.70–4.57 (m, 1H), 3.77 (brs, 1H, OH), 1.28–1.25 (m, 9H), 1.18 (d, J = 6.2 Hz, 3H).¹³C NMR (100.61 MHz, CDCl₃) δ 135.62 (d, J = 2.3 Hz), 133.72 (d, J = 3.8 Hz), 128.66 (d, J = 5.7 Hz, two carbon), 128.33 (d, J = 2.6 Hz, two carbon), 72.28 (d, J = 7.4 Hz), 71.93 (d, J = 7.7 Hz),

70.51 (d, J = 160.8 Hz), 24.26 (d, J = 3.3 Hz), 24.12 (d, J = 3.7 Hz), 24.03 (d, J = 5.0 Hz), 23.78 (d, J = 5.4 Hz).³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 19.11 (s). HRMS (ESI, M+H⁺) m/z calcd for C₁₃H₂₁O₄PCl: 307.0866, found 307.0865.



Diisopropyl (*R***)-(hydroxy(4-(trifluoromethyl)phenyl)methyl)phosphonate (4m):** Yield = 91%; $[\alpha]^{24}_{D}$ = +11.4 (c 1.05, CHCl₃). HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 7.86 min (*S*, minor), t_{R} = 8.79min (*R*, major); e.r. = 72:28. ¹H NMR (400.13 MHz, CDCl₃) δ 7.61 (s, 4H), 5.04 (dd, *J* =

11.5, 4.6 Hz, 1H), 4.74–4.59 (m, 2H), 3.77 (m, 1H, OH), 1.29–1.25 (m, 9H), 1.20 (d, J = 6.2 Hz, 3H). ¹³C NMR (100.61 MHz, CDCl₃) δ 141.43, 129.89 (qd, J = 32.4, 3.4 Hz), 127.55 (d, J = 5.4 Hz), 125.17–124.61 (m, two carbons), 124.29 (q, J = 273.1 Hz), 72.51 (d, J = 7.4 Hz), 72.05 (d, J = 7.8 Hz), 70.56 (d, J = 160.6 Hz), 24.20 (d, J = 3.2 Hz), 24.03 (d, J = 3.6 Hz), 24.01 (d, J = 4.9 Hz), 23.70 (d, J = 5.4 Hz). ³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 18.71 (d, J = 2.4 Hz). HRMS (ESI, M+H⁺) m/z calcd for C₁₄H₂₁O₄PF₃: 341.1130, found 341.1127.



Diisopropyl (*R***)-(hydroxy(naphthalen-2-yl)methyl)phosphonate (4n):** Yield = 95%; $[\alpha]^{24}_{D}$ = +19.0 (c = 1.05, CHCl₃). HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 13.76 min (*R*, major), t_{R} = 15.67 min (*S*, minor); e.r. = 88.5:11.5. ¹H NMR (400.13 MHz, CDCl₃) δ 7.96 (brs, 1H),

7.84–7.82 (m, 2H), 7.61 (dt, *J* = 8.6, 1.5 Hz, 1H), 7.49–7.46 (m, 2H), 5.14 (d, *J* = 10.7 Hz, 1H), 4.70–4.57 (m, 2H), 3.51 (brs, 1H, OH), 1.28 (d, *J* = 6.2 Hz, 3H), 1.27 (d, *J* = 6.2 Hz, 3H), 1.24 (d, *J* = 6.2 Hz, 3H), 1.13 (d, *J* = 6.2 Hz, 3H). ¹³C NMR (100.61 MHz, CDCl₃) δ 134.80 (d, *J* = 2.2 Hz), 133.15 (d, *J* = 2.5 Hz), 133.06 (d, *J* = 2.2 Hz), 128.11 (d, *J* = 1.2 Hz), 127.67 (d, *J* = 1.3 Hz), 127.57 (d, *J* = 2.0 Hz), 126.31 (d, *J* = 7.6 Hz), 125.99 (s), 125.92 (d, *J* = 1.1 Hz), 125.43 (d, *J* = 4.3 Hz), 72.05 (d, *J* = 7.4 Hz), 71.71 (d, *J* = 7.7 Hz), 71.17 (d, *J* = 161.2 Hz), 24.21 (d, *J* = 3.1 Hz), 24.08 (d, *J* = 3.6 Hz), 23.96 (d, *J* = 5.0 Hz), 23.67 (d, *J* = 5.5 Hz).³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 19.71 (s). HRMS (ESI, M+H⁺) *m/z* calcd for C₁₇H₂₄O₄P: 323.1412, found 323.1411.



Diisopropyl (*R*)-(hydroxy(naphthalen-1-yl)methyl)phosphonate (4o): Yield = 78%; [α]²⁴_D = +37.3(c 1.07, CHCl₃). HPLC analysis: Chiralpak IC column, Hexane/*i*-PrOH ^{O OiPr} 90:10, 1 mL/min, λ = 195 nm, t_{R} = 18.78 min (*S*, minor), t_{R} = 20.78 min (*R*, major); e.r. = 67.5:32.5. ¹H NMR (400.13 MHz, CDCl₃) δ 8.09 (d, *J* = 8.3 Hz, 1H), 7.90–7.80

(m, 3H), 7.53–7.45 (m, 3H), 5.80 (dd, J = 11.8, 3.2 Hz, 1H), 4.69–4.60 (m, 1H), 4.58–4.47 (m, 1H), 4.08 (brs, 1H, OH), 1.26 (d, J = 6.2 Hz, 3H), 1.19 (d, J = 6.1 Hz, 3H), 1.18 (d, J = 6.1 Hz, 3H), 0.87 (d, J = 6.2 Hz, 3H).¹³C NMR (100.61 MHz, CDCl₃) δ 133.57 (d, J = 1.3 Hz), 133.54 (d, J = 1.8 Hz), 131.11 (d, J = 6.1 Hz), 128.55 (s), 128.41 (d, J = 3.4 Hz), 125.72 (s), 125.66 (d, J = 6.1 Hz), 125.46 (s), 125.32 (d, J = 3.4 Hz), 124.19 (s), 124.19 (s), 72.21 (d, J = 7.5 Hz), 71.70 (d, J = 7.8 Hz), 67.26 (d, J = 163.5 Hz), 24.24 (d, J = 3.0 Hz), 23.97 (d, J = 4.9 Hz), 23.92 (d, J = 6.5 Hz), 23.26 (d, J = 5.6 Hz).³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 20.21 (s). HRMS (ESI, M+H⁺) *m/z* calcd for C₁₇H₂₄O₄P: 323.1412, found 323.1411.

Diisopropyl (*R*)-(furan-2-yl(hydroxy)methyl)phosphonate (4p): Yield = 96%; $[\alpha]^{24}_{D}$ = +12.16 (c 1.03, CHCl₃). HPLC analysis: Chiralpak AS-H column, Hexane/*i*-PrOH 90:10, 1 mL/min, λ = 195 nm, t_{R} = 8.10 min (*R*, major), t_{R} = 9.20 min (*S*, minor); e.r. = 66:34. ¹H NMR (400.13 MHz, CDCl₃) δ 7.44 (d, *J* = 0.8 Hz, 1H), 6.53 (t, *J* = 2.9 Hz, 1H), 6.40 (dd, *J* = 3.1, 1.9 Hz, 1H), 4.95 (d, *J* = 13.4 Hz, 1H), 4.83–4.64 (m, 2H), 1.37–1.32 (m, 9H), 1.20 (d, *J* = 6.2 Hz, 3H).¹³C NMR (100.61 MHz, CDCl₃) δ 150.74 (d, *J* = 2.5 Hz), 142.36 (d, *J* = 2.5 Hz), 110.65 (d, *J* = 1.9 Hz), 109.09 (d, *J* = 5.8 Hz), 72.30 (d, *J* = 7.2 Hz), 71.88 (d, *J* = 7.3 Hz), 64.94 (d, *J* = 168.7 Hz), 24.23 (d, *J* = 3.0 Hz), 24.08 (d, *J* = 3.6 Hz), 23.88 (d, *J* = 4.9 Hz), 23.56 (d, *J* = 5.4 Hz).³¹P (CDCl₃, 161.97 MHZ) δ (ppm) = 17.56 (s). HRMS (ESI, M+H⁺) *m/z* calcd for C₁₁H₂₀O₅P: 263.1048, found 263.1048.



IV. 1H and 13C NMR Spectra of phosphonylation products 4a-p

May24-2017 Ta117 HP Me phosphite	36.49 36.47 28.55 28.55 28.51 22.22 27.14 27.14	84.2 2.57 2.58 2.58 2.58 2.58	4.10 3.81 3.74	
13C{1H} CDCl3 /opt/topspin3.2 am2n1 46			2 2 2 2	
QН				
OMe				
O OMe				
4b				

	· · · · · · · · ·			





































C



















V. HPLC chromatogram of phosphonylation products 4a-p

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta120 rac 2.lcd Sample Name Vail # : 1 Injection Volume : 20 uL Data File Name : Ta120 rac 2.lcd Method File Name : IC 90-10 70min 1.0 mL min.lcm Report File Name : Default.lcr Data Acquired : 04/05/2017 17:58:53

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta120 rac 2.lcd



1 PDA Multi 1/195nm 4nm

PeakTable

	PDA Ch1 1	95nm 4nm		F	Cak I able
[Peak#	Ret. Time	Area	Height	Area %
	1	41.160	17384648	291320	50.124
	2	44.630	17298456	260856	49.876
	Total		34683104	552177	100.000

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta117 HP Chir (MeO)P3.lcd ame : Ta117 HP Chir (MeO)P3 :5

Sample Mame
Vail #
Injection Volume
Data File Name
Method File Name
Report File Name
Data Acquired

: 10 uL
: Ta117 HP Chir (MeO)P3.lcd
: IC 90-10 60min 1.0 mL min.lcm
: Default.lcr
: 23/05/2017 12:02:10

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta117 HP Chir (MeO)P3.lcd



PDA Ch1 1	95nm 4nm		Pe	eakTable
Peak#	Ret. Time	Area	Height	Area %
1	41.770	3338480	54874	15.374
2	45.198	18376174	275495	84.626
Total		21714654	330369	100.000

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta4 rac 1.lcd Sample Name : Ta4 rac 1 Vail # :1 : 12 uL : Ta4 rac 1.lcd Injection Volume Data File Name Method File Name : IC 90-10 40min 1.0 mL min.lcm Report File Name : Default.lcr Data Acquired : 04/05/2017 11:36:05



1 PDA Multi 1/195nm 4nm

PDA Ch1 1	95nm 4nm		Pe	eakTable
Peak#	Ret. Time	Area	Height	Area %
1	27.078	5008103	120671	49.868
2	32,128	5034694	100626	50.132
Total		10042797	221297	100.000

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta111 chir 1.lcd : Ta111 chir 1

Sample Name Vail # Injection Volume Data File Name

2 : 16 uL

Method File Name Report File Name Data Acquired

: Ta111 chir 1.lcd : IC 90-10 40min 1.0 mL min.lcm



C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta111 chir 1.lcd



		Pe	eakTable
;	Area	Height	Are

	PDA Ch1 105nm 4nm				
İ	Peak#	Ret Time	Area	Height	Area %
1	1	26.966	24330152	645041	84.542
1	2	32.140	4448495	90173	15.458
1	Total		28778647	735214	100.000

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta122 rac 2.lcd Sample Name : Ta122 rac 2 Vail # : 5 Injection Volume : 12 uL : Ta122 rac 2.lcd Data File Name Method File Name : IC 90-10 30min 1.0 mL min.lcm **Report File Name** : Default.lcr Data Acquired : 04/05/2017 21:20:42



1 PDA Multi 1/195nm 4nm

PeakTable

P	DA Chi i	95nm 4nm			
	Peak#	Ret. Time	Area	Height	Area %
Γ	1	16.515	11302496	446405	50.530
Γ	2	19.096	11065509	366576	49.470
	Total		22368005	812981	100.000

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta119 chir 2.lcd : Ta119 chir 2

Sample Name
Vail #
Injection Volume
Data File Name
Method File Name
Report File Name
Data Acquired

: 6
: 12 uL
: Ta119 chir 2.lcd
: IC 90-10 30min 1.0 mL min.lcm
: Default.lcr
: 04/05/2017 21:51:07



PDA Ch1 1	PDA Ch1 195nm 4nm						
Peak#	Ret, Time	Area	Height	Area %			
1	16.491	15101682	616175	78.521			
2	19.115	4130916	133744	21.479			
Total		19232598	749919	100.000			

 C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta121 rac 2.lcd

 Sample Name
 : Ta121 rac 2

 Vail #
 : 3

 Injection Volume
 : 12 uL

 Data File Name
 : Ta121 rac 2.lcd

 Method File Name
 : IC 90-10 30min 1.0 mL min.lcm

 Pata Acquired
 : 04/05/2017 20:19:47

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta121 rac 2.lcd mAU PDA Multi 1 12.362 ОН . OiPr 300 17.062 `0iPr Ö rac 4d 200 100 0 20 5 10 25 ò 15 min

1 PDA Multi 1/195nm 4nm

PeakTable

2DA Ch1 195nm 4nm					
Peak#	Ret, Time	Area	Height	Area %	
1	12.362	6688097	366979	50.958	
2	17.062	6436522	245507	49.042	
Total		13124619	612486	100.000	

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta118 chir 2.lcd : Ta118 chir 2 : 4

Sample Name Vail # Injection Volume Data File Name Method File Name Report File Name Data Acquired

: 12 uL		
• Ta118	chir 2	led

: IC 90-10 30min 1.0 mL min.lcm

- : Default.lcr
 - : 04/05/2017 20:50:15

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta118 chir 2.lcd



PDA Ch1 1	PeakTable PDA Ch1 195nm 4nm						
Peak#	Ret. Time	Area	Height	Area %			
1	12.337	17776715	1148528	88.443			
2	17.071	2323016	90336	11.557			
Total		20099732	1238865	100.000			



C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta155 2-MeO rac.lcd mAU PDA Multi 1 25.609 200-MeO ΟН .∕OiPr `0iPr 150іі О 48.933 rac 4e 100-50 0 10 20 30 40 50 min

1 PDA Multi 1/195nm 4nm

PeakTable

1	PDA Ch1 195nm 4nm				
	Peak#	Ret. Time	Area	Height	Area %
	1	25,609	8212843	202857	49.954
	2	48,933	8227899	100659	50.046
	Total		16440742	303517	100.000

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta155 2-MeO chir.lcd : Ta155 2-MeO chir

Sample Name Vail # Injection Volume Data File Name Method File Name Report File Name Data Acquired

: 12 : 12 uL : Ta155 2-MeO chir.lcd : IC 90-10 60min 1.0 mL min.lcm : Default.lcr : 21/06/2017 00:33:57



PDA Ch1 1	95nm 4nm		Pe	eakTable
Peak#	Ret. Time	Area	Height	Area %
1	25,556	15641107	394720	72.099
2	48.976	6052799	76296	27.901
Total		21693906	471015	100,000





1 PDA Multi 1/195nm 4nm

PeakTable

PDA Ch1 195nm 4nm

Peak#	Ret. Time	Area	Height	Area %
1	34.725	13729534	240463	50.230
2	41.168	13603590	195595	49.770
Total		27333124	436059	100.000

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta156 3-MeO chir.lcd : Ta156 3-MeO chir

Sample Name Vail # Injection Volume Data File Name Method File Name Report File Name Data Acquired

: 12 uL : Ta156 3-MeO chir.lcd : IC 90-10 60min 1.0 mL min.lcm : Default.lcr

: 10

: 20/06/2017 22:33:01

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta156 3-MeO chir.lcd



1 PDA Multi 1/195nm 4nm

Total

PeakTable

393134

Area %

11.511 88.489

100.000

PDA Ch1 1	95nm 4nm		1
Peak#	Ret. Time	Area	Height
1	34.821	3050956	53011
2	41.011	23454606	340123

26505562



mAU PDA Multi 1 19.174 ОН OiPr 27.986 200-`OiPr іі О MeO rac 4g 100-0 10 5 15 20 25 30 35 Ċ min

1 PDA Multi 1/195nm 4nm

PeakTable

PDA Ch1 1	95nm 4nm		1.	Curruble
Peak#	Ret. Time	Area	Height	Area %
1	19.174	8015197	266049	50.370
2	27.986	7897333	173523	49.630
Total		15912531	439573	100.000

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta157 4-MeO chir.lcd : Ta157 4-MeO chir

Sample Name
Vail #
Injection Volume
Data File Name
Method File Name
Report File Name
Data Acquired

: 12 uL : Ta157 4-MeO chir.lcd : IC 90-10 40min 1.0 mL min.lcm : Default.lcr : 20/06/2017 20:52:05



PeakTable

PDA Ch1 1	95nm 4nm			
Peak#	Ret. Time	Area	Height	Area %
1	19.143	13031807	443553	85.667
2	28.031	2180380	49292	14.333
Total		15212187	492845	100.000





1 PDA Multi 1/200nm 4nm

PeakTable

PDA Ch1 200nm 4nm						
Peak#	Ret. Time	Area	Height	Area %		
1	14.414	11202520	499419	50.628		
2	23.279	10924534	285423	49.372		
Total		22127054	784842	100.000		

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta158 4-Methyl chir.lcd ne : Ta158 4-Methyl chir

Sample Name
Vail #
Injection Volume
Data File Name
Method File Name
Report File Name
Data Acquired

:6
: 12 uL
: Ta158 4-Methyl chir.lcd
: IC 90-10 30min 1.0 mL min.lcm
: Default.lcr
: 20/06/2017 19:41:09





PDA Ch1 2	200nm 4nm		Pe	eakTable
Peak#	Ret. Time	Area	Height	Area %
1	14.400	19214283	902031	86.592
2	23.314	2975034	80957	13.408
Total		22189317	982988	100.000





1 PDA Multi 1/195nm 4nm

PeakTable

PDA Ch1 1	95nm 4nm		10	Cak l'able
Peak#	Ret. Time	Area	Height	Area %
1	9.102	7228657	636211	51.788
2	12.150	6729463	368507	48.212
Total		13958120	1004718	100.000

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta161 chir 2-F.lcd : Ta161 chir 2-F

Sample Name
Vail #
Injection Volume
Data File Name
Method File Name
Report File Name
Data Acquired

750

mAU

: 2 : 9 uL : Ta161 chir 2-F.lcd : IC 90-10 20min 1.0 mL min.lcm : Default.lcr





PeakTable

			1.	Carladic
PDA Ch1	195nm 4nm			
Peak#	Ret. Time	Area	Height	Area %
1	9.109	8263565	742970	66.481
2	12,153	4166462	223998	33.519
Tota	1	12430026	966968	100.000

PDA Multi 1



C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta162 rac 3-F.lcd mAU PDA Multi 1 7.608 OH .OiPr 8.373 750-`OiPr 0 rac 4j 500-250 0-0.0 10.0 2.5 5.0 7.5 12.5 min

1 PDA Multi 1/195nm 4nm

PeakTable

PDA Ch1 1	95nm 4nm		1.	cakrable
Peak#	Ret. Time	Area	Height	Area %
1	7.608	7861871	885309	51.450
2	8.373	7418733	658652	48.550
Total		15280604	1543961	100.000

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta162 chir 3-F.lcd : Ta162 chir 3-F

Sample Name	
Vail #	
Injection Volume	
Data File Name	
Method File Name	
Report File Name	
Data Acquired	

: 4
: 9 uL
: Ta162 chir 3-F.lcd
: IC 90-10 15min 1.0 mL min.lcm
: Default.lcr
: 19/06/2017 13:15:31



PDA Ch1 1	95nm 4nm		P	eakTable
Peak#	Ret. Time	Area	Height	Area %
1	7.602	10305783	1101493	81.215
2	8.376	2383703	189995	18.785
Total		12689487	1291488	100.000



C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta163 rac 4-F.lcd mAU PDA Multi 1 567 ΟН 9.670 _OiPr 500-`OiPr іі О rac 4k 250 0 2.5 5.0 7.5 10.0 12.5 0.0 min

1 PDA Multi 1/195nm 4nm

PeakTable

PDA Ch	1 19	95nm 4nm		1	Carlable
Peak#		Ret. Time	Area	Height	Area %
	1	8.567	7177471	605535	50.917
	2	9.670	6918870	488002	49.083
To	tal		14096341	1093537	100.000

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta163 chir 4-F.lcd : Ta163 chir 4-F

Sample Name	: Ta163 chir 4-F
Vail #	: 6
Injection Volume	: 9 uL
Data File Name	: Ta163 chir 4-F.lcd
Method File Name	: IC 90-10 15min 1.0 mL min.lcm
Report File Name	: Default.lcr
Data Acquired	: 19/06/2017 13:46:28

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta163 chir 4-F.lcd



PDA Ch1 1	95nm 4nm		Р	eakTable
Peak#	Ret. Time	Area	Height	Area %
1	8.547	14140058	1319686	88.969
2	9.656	1753201	115741	11.031
Total		15893259	1435427	100.000





1 PDA Multi 1/195nm 4nm

PeakTable

PDA Ch1 195nm 4nm							
Peak#	Ret. Time	Area	Height	Area %			
1	6.652	7438333	590925	51.193			
2	8.381	7091714	393934	48.807			
Total		14530047	984859	100.000			

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta164 chir 4-Cl.lcd : Ta164 chir 4-Cl

Sample Name
Vail #
Injection Volume
Data File Name
Method File Name
Report File Name
Data Acquired

: 2 : 9 uL : Ta164 chir 4-Cl.lcd : AS-H 90-10 15min 1.0 mL min.lcm : Default.lcr : 19/06/2017 10:19:55





PDA Ch1 195nm 4nm						
Peak#	Ret. Time	Area	Height	Area %		
1	6.659	16203204	1417271	85.955		
2	8.408	2647703	147780	14.045		
Total		18850906	1565051	100.000		



C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta165 rac 4-CF3.lcd



1 PDA Multi 1/195nm 4nm

....

PeakTable

PDA Chi I	95nm 4nm			
Peak#	Ret, Time	Area	Height	Area %
1	7.860	5671921	499621	50,500
2	8.800	5559678	419930	49.500
Total		11231598	919550	100.000

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta165 chir 4-CF3.lcd : Ta165 chir 4-CF3

Sample Name
Vail #
Injection Volume
Data File Name
Method File Name
Report File Name
Data Acquired

: 9 uL : Ta165 chir 4-CF3.lcd : IC 95-5 15min 1.0 mL min.lcm : Default.lcr : 19/06/2017 14:50:37





1 PDA Multi 1/195nm 4nm

PeakTable PDA Ch1 195nm 4nm Height Peak# Ret. Time Area Area % 27.928 72.072 7.856 4618824 402751 11919363 1052148 8.789 16538187 1454899 100.000 Total



C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta160 2-Naphthyl rac.lcd mAU PDA Multi 1 15.672 13.77 ОН 400-. OiPr `0iPr Ö 300rac 4n 200 100 0-5 15 10 20 Ó min

1 PDA Multi 1/195nm 4nm

PeakTable

1	PDA Ch1 195nm 4nm							
ſ	Peak#	Ret. Time	Area	Height	Area %			
ſ	1	13.777	10065690	467846	49.864			
ſ	2	15.672	10120522	401351	50.136			
	Total		20186213	869196	100.000			

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta160 2-Naphthyl chir.lcd Sample Name : Ta160 2-Naphthyl chir Vail # :2

Vail #
Injection Volume
Data File Name
Method File Name
Report File Name
Data Acquired

: 2 : 4 uL : Ta160 2-Naphthyl chir.lcd : IC 90-10 25min 1.0 mL min.lcm : Default.lcr : 20/06/2017 17:44:18



PDA Ch1 195nm 4nm						
Peak#	Ret. Time	Area	Height	Area %		
1	13.765	32192049	1804889	88.517		
2	15.676	4176366	168239	11.483		
Total		36368415	1973128	100.000		

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta159 1-Naphthyl rac.lcd e : Ta159 1-Naphthyl rac Sample Name Vail # : 3 Injection Volume Data File Name Method File Name Report File Name Data Acquired : 4 uL : Ta159 1-Naphthyl rac.lcd : IC 90-10 30min 1.0 mL min.lcm : Default.lcr : 20/06/2017 18:09:45



1 PDA Multi 1/195nm 4nm

PeakTable

PDA Ch1 195nm 4nm						
Peak#	Ret. Time	Area	Height	Area %		
1	18.773	8616140	282107	50.132		
2	20.809	8570597	248400	49.868		
Total		17186737	530507	100.000		

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta159 1-Naphthyl chir.lcd e : Ta159 1-Naphthyl chir · 4 Sample Name

vall #	. 4
Injection Volume	: 4 uL
Data File Name	: Ta159 1-Naphthyl chir.lcd
Method File Name	: IC 90-10 30min 1.0 mL min.lcm
Report File Name	: Default.lcr
Data Acquired	: 20/06/2017 18:40:13

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta159 1-Naphthyl chir.lcd



1 PDA Multi 1/195nm 4nm

PeakTable

PDA Ch1 1	95nm 4nm		1.	cak I dole
Peak#	Ret. Time	Area	Height	Area %
1	18.781	10867848	360975	32.585
2	20.783	22484389	721960	67.415
Total		33352237	1082935	100.000

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta166 rac fural.lcd Sample Name : Ta166 rac fural Vail # : 3 Injection Volume : 9 uL Data File Name : Ta166 rac fural.lcd Method File Name : AS-H 90-10 45min 1.0 mL min.lcm Report File Name : Default.lcr Data Acquired : 19/06/2017 10:35:22



1 PDA Multi 1/195nm 4nm

DDA Ch1 105nm 4nm

PeakTable

PDA Chi 1951ini 4hini						
Peak#	Ret. Time	Area	Height	Area %		
1	8.095	10080925	729456	51.029		
2	9.191	9674325	590515	48.971		
Total		19755250	1319971	100.000		

C:\LabSolutions\Data\projet2\AM2N1\Tahar\Hydrophosphonylation\Ta166 chir fural.lcd : Ta166 chir fural

Sample Name Vail # Injection Volume Data File Name Method File Name Report File Name Data Acquired

: Ta166 chir fural.lcd : AS-H 90-10 15min 1.0 mL min.lcm : Default.lcr

: 19/06/2017 10:50:48

: 4

: 9 uL

mAU

 $\label{eq:labSolutions} C: LabSolutions Data projet \\ 2 AM2N1 \\ Tahar \\ Hydrophosphonylation \\ Ta166 \ chir \ fural. \\ Icd \\ C: LabSolutions \\ C: LabSolut$



1 PDA Multi 1/195nm 4nm

DDA Ch1 105

PeakTable

PDA Chi 195nin 4nm						
Peak#	Ret. Time	Area	Height	Area %		
1	8.108	11816767	933993	65.971		
2	9.200	6095294	352847	34.029		
Total		17912061	1286840	100.000		